WO2001060998A3 - Small oligonucleotides with anti-tumor activity - Google Patents

Small oligonucleotides with anti-tumor activity Download PDF

Info

Publication number
WO2001060998A3
WO2001060998A3 PCT/US2001/040159 US0140159W WO0160998A3 WO 2001060998 A3 WO2001060998 A3 WO 2001060998A3 US 0140159 W US0140159 W US 0140159W WO 0160998 A3 WO0160998 A3 WO 0160998A3
Authority
WO
WIPO (PCT)
Prior art keywords
bases
bcl
antisense oligonucleotides
tumor activity
oligonucleotide compositions
Prior art date
Application number
PCT/US2001/040159
Other languages
French (fr)
Other versions
WO2001060998A2 (en
WO2001060998A9 (en
Inventor
Ana M Tari
Gabriel Lopez-Berestein
Yolanda Gutierrez-Puente
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Priority to CA002398945A priority Critical patent/CA2398945A1/en
Priority to EP01927361A priority patent/EP1255828A2/en
Publication of WO2001060998A2 publication Critical patent/WO2001060998A2/en
Publication of WO2001060998A3 publication Critical patent/WO2001060998A3/en
Publication of WO2001060998A9 publication Critical patent/WO2001060998A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/311—Phosphotriesters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Abstract

The present invention provides short antisense oligonucleotide compositions and methods for their use in the treatment of Bcl-2-associated diseases like cancer, such as follicular lymphoma (FL). The antisense oligonucleotides contain sequences that hybridize to Bcl-2 nucleic acids, the gene products of which are known to interact with the tumorigenic protein Bcl-2. The use of novel short antisense oligonucleotides, from 7 bases to 9 bases in length, is described in this invention. The invention also describes certain specific sequences which are longer than 9 bases and are 11 or 15 bases long. Used alone, or in conjunction with other antisense oligonucleotides, these antisense oligonucleotide compositions inhibit the proliferation of cancer cells.
PCT/US2001/040159 2000-02-18 2001-02-20 Small oligonucleotides with anti-tumor activity WO2001060998A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002398945A CA2398945A1 (en) 2000-02-18 2001-02-20 Small oligonucleotides with anti-tumor activity
EP01927361A EP1255828A2 (en) 2000-02-18 2001-02-20 Small oligonucleotides with anti-tumor activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/506,979 2000-02-18
US09/506,979 US7704962B1 (en) 1997-10-03 2000-02-18 Small oligonucleotides with anti-tumor activity

Publications (3)

Publication Number Publication Date
WO2001060998A2 WO2001060998A2 (en) 2001-08-23
WO2001060998A3 true WO2001060998A3 (en) 2002-02-28
WO2001060998A9 WO2001060998A9 (en) 2008-07-17

Family

ID=24016787

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/040159 WO2001060998A2 (en) 2000-02-18 2001-02-20 Small oligonucleotides with anti-tumor activity

Country Status (4)

Country Link
US (1) US7704962B1 (en)
EP (1) EP1255828A2 (en)
CA (1) CA2398945A1 (en)
WO (1) WO2001060998A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7284709B2 (en) 2017-04-19 2023-05-31 バイオ－パス ホールディングス， インコーポレイテッド P-ethoxy nucleic acids for BCL2 inhibition

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004046327A2 (en) 2002-11-14 2004-06-03 Genta Salus Llc Inhibitory oliogonucleotides targeted to bcl-2
EP1633770B1 (en) * 2003-06-13 2015-04-29 Alnylam Europe AG Double-stranded ribonucleic acid with increased effectiveness in an organism
IL282614B2 (en) 2015-02-06 2024-02-01 Cell Idx Inc Antigen-coupled immunoreagents
WO2017066643A1 (en) * 2015-10-14 2017-04-20 Bio-Path Holding, Inc. P-ethoxy nucleic acids for liposomal formulation
EP3485275A4 (en) * 2016-07-18 2020-06-17 Cell IDX, Inc. Antigen-coupled hybridization reagents
MX2019003070A (en) 2016-09-16 2019-10-14 Bio Path Holdings Inc Combination therapy with liposomal antisense oligonucleotides.
WO2018195281A1 (en) * 2017-04-19 2018-10-25 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for igf-1r inhibition
CA3058018A1 (en) 2017-04-19 2018-10-25 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for stat3 inhibition
CA3057974A1 (en) * 2017-04-19 2018-10-25 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for igf-1r inhibition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5734033A (en) * 1988-12-22 1998-03-31 The Trustees Of The University Of Pennsylvania Antisense oligonucleotides inhibiting human bcl-2 gene expression
WO1998014172A1 (en) * 1996-10-04 1998-04-09 Board Of Regents, The University Of Texas System Inhibition of bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
WO1998056905A1 (en) * 1997-06-09 1998-12-17 Novartis Ag Oligonucleotide derivatives

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621479A5 (en) 1977-08-05 1981-02-13 Battelle Memorial Institute
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4480041A (en) 1982-07-09 1984-10-30 Collaborative Research, Inc. Use of phosphotriester intermediates for preparation of functionalized liposomes
FR2540122B1 (en) 1983-01-27 1985-11-29 Centre Nat Rech Scient NOVEL COMPOUNDS COMPRISING A SEQUENCE OF OLIGONUCLEOTIDE LINKED TO AN INTERCALATION AGENT, THEIR SYNTHESIS PROCESS AND THEIR APPLICATION
US4721612A (en) 1984-04-12 1988-01-26 The Liposome Company, Inc. Steroidal liposomes
US5015568A (en) 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US5202429A (en) 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US5049388A (en) 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US5094785A (en) 1986-12-10 1992-03-10 Ciba Corning Diagnostics Corp. Process for stabilizing liposomes
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5030442A (en) 1987-03-30 1991-07-09 Liposome Technology, Inc. Non-crystalline minoxidil composition
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US4950432A (en) 1987-10-16 1990-08-21 Board Of Regents, The University Of Texas System Polyene microlide pre-liposomal powders
US5178875A (en) 1991-01-14 1993-01-12 The Board Of Regents, The University Of Texas System Liposomal-polyene preliposomal powder and method for its preparation
US4924624A (en) 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US5188897A (en) 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
EP0397774A1 (en) 1988-02-04 1990-11-22 Board Of Regents, The University Of Texas System Formulation and use of retinoids in treatment of cancer and other diseases
US5098890A (en) 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5831066A (en) * 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US5248671A (en) 1989-02-15 1993-09-28 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US5087617A (en) 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
FR2644080A1 (en) 1989-03-13 1990-09-14 Trizac Jacques DEVICE FOR FILTRATION AND EVACUATION OF SMALL PARTICLES, WASTES AND TRENDS OF VARIOUS NATURE
WO1990012595A1 (en) 1989-04-18 1990-11-01 Vestar, Inc. Liposomal targeting of ischemic tissue
US5112962A (en) 1989-04-19 1992-05-12 Northwestern University Labile anchors for solid phase polynucleotide synthesis
US5227170A (en) 1989-06-22 1993-07-13 Vestar, Inc. Encapsulation process
US5100662A (en) 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
CA2033725C (en) 1990-01-24 2001-05-29 Folker Pittrof Pharmaceutical and cosmetic compositions containing a salt of cholanic acid
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
EP0527818A4 (en) 1990-04-30 1993-09-15 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of arachidonic acid metabolism
US5665710A (en) 1990-04-30 1997-09-09 Georgetown University Method of making liposomal oligodeoxynucleotide compositions
ATE151076T1 (en) 1990-07-02 1997-04-15 Hoechst Ag OLIGONUCLEOTIDE ANALOGUES WITH TERMINALS 3'-3' OR 5'-5' INTERNUCLEOTIDE LINKAGES
US5135917A (en) 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
WO1992005272A1 (en) 1990-09-17 1992-04-02 The Regents Of The University Of California Method and composition for controlling proliferation of cells
US5271941A (en) 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
DE4110085A1 (en) 1991-03-27 1992-10-01 Boehringer Ingelheim Int New 2'O-alkyl-oligo-ribonucleotide(s) with 8-35 nucleotide units - useful as anti-sense oligo-nucleotide(s), primers and probes
FR2677272B1 (en) 1991-06-05 1995-03-03 Biovecteurs As PARTICULATE VECTOR WITH SELECTIVE TROPISM, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION.
US5525719A (en) 1991-08-30 1996-06-11 Chemgenes Corporation N-protected-2'-O-methyl-and N-protected-3'-O-methyl-ribonucleosides and their phosphoramidite derivatives
US6030954A (en) * 1991-09-05 2000-02-29 University Of Connecticut Targeted delivery of poly- or oligonucleotides to cells
DE69233046T2 (en) 1991-10-24 2004-03-04 Isis Pharmaceuticals, Inc., Carlsfeld DERIVATIZED OLIGONUCLEOTIDS WITH IMPROVED CAPACITY
EP0616644B1 (en) 1991-12-04 2003-07-02 E.I. Du Pont De Nemours And Company Fatty acid desaturase genes from plants
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
WO1993020200A1 (en) 1992-04-02 1993-10-14 Imperial Cancer Research Technology Limited Modified cells and method of treatment
US5279957A (en) 1992-04-30 1994-01-18 Washington University cDNA encoding human phospholipase A2 polypeptide
IT1255770B (en) 1992-05-22 1995-11-15 Consiglio Nazionale Ricerche ANTISENSE OLIGONUCLEOTIDES FOR ANTI-CANCER ACTIVITIES, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, AND THEIR USE
US5320962A (en) 1992-07-22 1994-06-14 Duke University DNA encoding the human A1 adenosine receptor
NL9201440A (en) 1992-08-11 1994-03-01 Univ Leiden Triantennary cluster glycosides, their preparation and application.
AU5092893A (en) 1992-09-02 1994-03-29 Georgetown University Method of encapsulating anthracycline glycosides in liposomes
US6001992A (en) 1999-01-07 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of novel anti-apoptotic bcl-2-related proteins
US6015886A (en) 1993-05-24 2000-01-18 Chemgenes Corporation Oligonucleotide phosphate esters
US5417978A (en) 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5539085A (en) 1993-08-20 1996-07-23 Onyx Pharmaceuticals, Inc. Bcl-2 and R-ras complex
US5622852A (en) 1994-10-31 1997-04-22 Washington University Bcl-x/Bcl-2 associated cell death regulator
FR2710074B1 (en) 1993-09-15 1995-12-08 Rhone Poulenc Rorer Sa GRB3-3 gene, its variants and their uses.
WO1995008350A1 (en) 1993-09-20 1995-03-30 Reed John C REGULATION OF bcl-2 GENE EXPRESSION
US5539094A (en) 1993-11-12 1996-07-23 La Jolla Cancer Research Foundation DNA encoding Bcl-2-associated proteins
US5583034A (en) 1994-02-22 1996-12-10 La Jolla Institute For Allergy And Immunology Enhancement of adoptosis using antisense oligonucleotides
US5651981A (en) 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
WO1995028497A1 (en) 1994-04-13 1995-10-26 La Jolla Cancer Research Foundation Interaction of proteins involved in a cell death pathway
US5696248A (en) 1994-06-15 1997-12-09 Hoechst Aktiengesellschaft 3'-modified oligonucleotide derivatives
US5908635A (en) 1994-08-05 1999-06-01 The United States Of America As Represented By The Department Of Health And Human Services Method for the liposomal delivery of nucleic acids
US5565337A (en) 1994-08-23 1996-10-15 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Hybridoma-producing NSO myeloma cell line
IT1275862B1 (en) 1995-03-03 1997-10-24 Consiglio Nazionale Ricerche ANTI-SENSE TRANSCRIPT ASSOCIATED WITH SOME TYPES OF TUMOR CELLS AND SYNTHETIC OLIGODEOXYNUCLEOTIDES USEFUL IN DIAGNOSIS AND TREATMENT
ATE206131T1 (en) 1995-03-13 2001-10-15 Aventis Pharma Gmbh PHOSPHONOMONOESTERNUCLIC ACIDS, METHOD FOR THEIR PRODUCTION AND THEIR USE
WO1996038176A1 (en) 1995-06-01 1996-12-05 Kishimoto, Tadamitsu Leukemic cell growth inhibitor containing antisense oligonucleotide derivative against wilms' tumor gene (wt1)
US6326487B1 (en) 1995-06-05 2001-12-04 Aventis Pharma Deutschland Gmbh 3 modified oligonucleotide derivatives
IL122290A0 (en) * 1995-06-07 1998-04-05 Inex Pharmaceuticals Corp Lipid-nucleic acid complex its preparation and use
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5981501A (en) * 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US5756122A (en) 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
ATE247971T1 (en) 1995-08-01 2003-09-15 Novartis Erfind Verwalt Gmbh LIPOSOMAL OLIGONUCLEOTIDE COMPOSITIONS
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
DE19532553A1 (en) 1995-09-04 1997-03-06 Hoechst Ag Process for the preparation of substituted N-ethyl-glycine derivatives
US6120794A (en) 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
US6958239B2 (en) * 1996-11-21 2005-10-25 Oligos Etc Inc. Three component chimeric antisense oligonucleotides
US5874224A (en) 1997-03-11 1999-02-23 Incyte Pharmaceuticals, Inc. Growth factor receptor binding protein
US5837838A (en) 1997-03-14 1998-11-17 The Burnham Institute Bax inhibitor proteins
US6126965A (en) 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
WO1998058630A1 (en) 1997-06-23 1998-12-30 Sequus Pharmaceuticals, Inc. Liposome-entrapped polynucleotide composition and method
US6277981B1 (en) 1997-07-03 2001-08-21 Thomas Jefferson University Method for design and selection of efficacious antisense oligonucleotides
US6136965A (en) 1998-07-02 2000-10-24 The Regents Of The University Of California Deoxynucleic alkyl and alkoxy thiourea compounds
US6211349B1 (en) 1998-12-30 2001-04-03 Oligos Etc., Inc. Protonated/acidified nucleic acids and methods of use
US6211162B1 (en) 1998-12-30 2001-04-03 Oligos Etc. Inc. Pulmonary delivery of protonated/acidified nucleic acids
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5734033A (en) * 1988-12-22 1998-03-31 The Trustees Of The University Of Pennsylvania Antisense oligonucleotides inhibiting human bcl-2 gene expression
WO1998014172A1 (en) * 1996-10-04 1998-04-09 Board Of Regents, The University Of Texas System Inhibition of bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
WO1998056905A1 (en) * 1997-06-09 1998-12-17 Novartis Ag Oligonucleotide derivatives

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
COTTER F E ET AL: "Human Bcl-2 antisense therapy for lymphomas", BIOCHIMICA ET BIOPHYSICA ACTA. GENE STRUCTURE AND EXPRESSION, ELSEVIER, AMSTERDAM, NL, vol. 1489, no. 1, 10 December 1999 (1999-12-10), pages 97 - 106, XP004275525, ISSN: 0167-4781 *
GLEAVE M E ET AL: "TARGETING BCL-2 GENE TO DELAY ANDROGEN-INDEPENDENT PROGRESSION AND ENHANCE CHEMOSENSITIVITY IN PROSTATE CANCER USING ANTISENSE BCL-2 OLIGODEOXYNUCLEOTIDES", UROLOGY, BELLE MEAD, NJ, US, vol. 54, no. 6A, SUPPL, December 1999 (1999-12-01), pages 36 - 46, XP000964819, ISSN: 0090-4295 *
JANSEN B ET AL: "BCL-2 ANTISENSE THERAPY CHEMOSENSITIZES HUMAN MELANOMA IN SCID MICE", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 4, no. 2, 1998, pages 232 - 234, XP001002592, ISSN: 1078-8956 *
ZEGLER A ET AL: "Induction of apoptosis in small cell lung cancer cells by antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence", JOURNAL OF THE NATIONAL CANCER INSTITUTE, US DEPT. OF HEALTH, EDICATIONAND WELFARE, PUBLIC HEALTH, US, vol. 89, no. 14, 16 July 1997 (1997-07-16), pages 1027 - 1036, XP002080869, ISSN: 0027-8874 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7284709B2 (en) 2017-04-19 2023-05-31 バイオ－パス ホールディングス， インコーポレイテッド P-ethoxy nucleic acids for BCL2 inhibition

Also Published As

Publication number Publication date
US7704962B1 (en) 2010-04-27
CA2398945A1 (en) 2001-08-23
EP1255828A2 (en) 2002-11-13
WO2001060998A2 (en) 2001-08-23
WO2001060998A9 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
EP0939621A4 (en) Inhibition of bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
Yamamoto et al. Lipofection of synthetic oligodeoxyribonucleotide having a palindromic sequence of AACGTT to murine splenocytes enhances interferon production and natural killer activity
RU95104940A (en) Method of incorporation of alkylphosphonothioate or arylphosphonothioate internucleotide linkage in oligonucleotide, method of oligonucleotide synthesis, method of gene expression inhibition, treatment method
CA2177732A1 (en) Antisense oligonucleotides having tumorigenicity-inhibiting activity
WO2003040366A3 (en) Inhibitor oligonucleotides and their use for specific repression of a gene
WO2000063364A3 (en) Methods and compositions for inhibiting the function of polynucleotide sequences
HK1203547A1 (en) Rna sequence-specific mediators of rna interference
EP2213736A3 (en) Method for inhibiting the expression of a target gene and medicine for treating a tumour illness
HU9403788D0 (en) Self-stabilized oligonucleotides as therapeutic agents
ATE174599T1 (en) BINDING COMPETENT OLIGOMERS CONTAINING 2',5' BONDS
AU4595399A (en) Antisense oligonucleotide constructs based on beta-arabinofuranose and its analogues
WO2001060998A3 (en) Small oligonucleotides with anti-tumor activity
WO1998054313A3 (en) Dna methyltransferase genomic sequences and antisense oligonucleotides
WO2003101386A3 (en) Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis
Lang et al. Guanosine‐rich oligodeoxynucleotides induce proliferation of macrophage progenitors in cultures of murine bone marrow cells
Kausch et al. Antisense oligonucleotide therapy in urology
AU8944801A (en) Chimeric antisense of arabinofuranose analogue and deoxyribose nucleotides
WO2001098522A3 (en) Positively-charged peptide nucleic acid analogs with improved properties
DE69736290D1 (en) INHIBITION OF THE GROWTH OF THE CHRONIC MYELOGENIC LEUKEMIC CELLS BY ANTISENS OLIGONUCLEOTIDES THAT ARE TARGETED TO GRB2
EP1322658A4 (en) Oligonucleotide modulation of her-1 expression
JP2006514546A5 (en)
EP1086116A4 (en) Compositions and methods for the pulmonary delivery of nucleic acids
AU2001258274A1 (en) Synthetic oligonucleotides as inducers of erythroid differentiation
WO2005049793A3 (en) Methods and compositions for combinatorial approaches to cancer gene therapy
Li et al. Syntheses and binding studies of oligonucleotides containing N-hydroxycarbamate linkages: potential DNA cleaving antisense oligomers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

WWE Wipo information: entry into national phase

Ref document number: 2398945

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001927361

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001927361

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001927361

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP